Bosutinib (BOS) vs imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the bfore trial

Category Primary study
JournalHaematologica
Year 2017
This article has no abstract
Epistemonikos ID: 2980037184baaca44161bf9b8fa467d9850bf0e5
First added on: Feb 09, 2025